Breast cancer risk in postmenopausal women using estradiol-progestogen therapy

Obstetrics and Gynecology

Volumn 113, Issue 1, 2009, Pages 65-73

  Lyytinen, Heli ^b   Pukkala, Eero ^b   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; EXPOSURE; FEMALE; FINLAND; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; REIMBURSEMENT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; ESTROGEN THERAPY; INCIDENCE; INTRADERMAL DRUG ADMINISTRATION; LUNG CARCINOMA; MIDDLE AGED; NOTE; ORAL DRUG ADMINISTRATION; PAGET NIPPLE DISEASE; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 60749103451     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31818e8cd6     Document Type: Article

References (40)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer [published erratum appears in Lancet 1997;350: 1484]. Lancet 1997;350:1047-59.
2. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormone treatment [published erratum appears in Hum Reprod Update 2006;12:331]. Hum Reprod Update 2005;111:545-60.
3. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668-78.
4. Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopausal hormones and breast cancer in a biracial population. Am J Public Health 2000;90:966-71.
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
6. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-12.
7. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
8. Breen N, A Cronin K, Meissner HI, Taplin SH, Tangka FK, Tiro JA, et al. Reported drop in mammography: is this cause for concern? Cancer 2007;109:2405-9.
9. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60.
10. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
11. Finnish Cancer Registry. Cancer in Finland 2002 and 2003. Available at: http://www.cancerregistry.fi/index-2pdf. Retrieved October 8, 2008.
12. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1998.
13. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-16.
14. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11.
15. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum appears in Lancet 2003;362:1160]. Lancet 2003;362:419-27.
16. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004;112:130-4.
17. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-7.
18. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999;32:141-5.
19. Pukkala E, Notkola V. Cancer incidence among Finnish farmers, 1979-93. Cancer Causes Control 1997;8:25-33.
20. Sarkeala T, Heinävaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer 2008;122:614-9.
21. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100: 1148-58.
22. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847-54.
23. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-41.
24. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003 ;97: 1387-92.
25. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008;123:933-41.
26. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600.
27. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
28. Opatrny L, DellAniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169-75.
29. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits-an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol 2006;22:303-17.
30. Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-8.
31. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:Rll.
32. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699-706.
33. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. IntJ Cancer 2006;118:1285-91.
34. Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 2008;17: 43-50.
35. Delgado RC, Lubian Lopez DM. Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 2001;38:147-56.
36. ManjerJ, MalinaJ, Berglund G, Bondeson L, GarneJP,Janzon L. Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int J Cancer 2001;92:919-22.
37. Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K, Pommier RF. The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 2002; 137: 1015-9.
38. Conner P. Breast response to menopausal hormone therapyaspects on proliferation, apoptosis and mammographic density. Ann Med 2007;39:28-41.
39. Castagnetta L, Granata OM, Cocciadiferro L, Saetta A, Polito L, Bronte G, et al. Sex steroids, carcinogenesis, and cancer progression. Ann N Y Acad Sci 2004;1028:233-46.
40. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 2008; 15: 393-400.